GLP-1 Agonists: What They Actually Do (Beyond Weight Loss)

GLP-1 (glucagon-like peptide-1) is an incretin hormone produced in the gut in response to food. It stimulates insulin release, suppresses glucagon, slows gastric emptying, and signals satiety to the brain. GLP-1 receptor agonists mimic this natural hormone with greater potency and much longer half-lives.

Early agents like liraglutide (Victoza) produced modest weight loss and glucose lowering. Semaglutide — marketed as Ozempic for diabetes and Wegovy for obesity — produces weight reduction averaging 10–15% of body weight in clinical trials. Tirzepatide (Mounjaro, Zepbound), which activates both GLP-1 and GIP receptors, has shown weight loss approaching 20–22% in the SURMOUNT-1 trial — results that begin to approach what bariatric surgery produces in some patients (Jastreboff et al., N Engl J Med, 2022).[7]

GLP-1 receptors are expressed in the pancreas and gut, but also in the heart, kidney, brain, liver, and blood vessel walls. That distribution matters — it's probably why the drug effects extend so far beyond glucose and weight.

Starting in 2016, the FDA required all new diabetes drugs to demonstrate cardiovascular safety in large outcomes trials. What the GLP-1 agonists showed wasn't just safety — it was active benefit.

The LEADER trial (liraglutide, n=9,340) showed a 13% reduction in the primary composite of cardiovascular death, nonfatal MI, and nonfatal stroke versus placebo, with a 22% reduction in cardiovascular mortality specifically.[1] SUSTAIN-6 (semaglutide, n=3,297) showed a 26% MACE reduction.[2] REWIND (dulaglutide, n=9,901) extended the findings to a broader population that included patients at risk for cardiovascular disease, not just those with established disease.[3]

The SELECT trial, published in 2023, was the critical expansion. It enrolled 17,604 patients with obesity and established cardiovascular disease but without type 2 diabetes — and found that semaglutide 2.4 mg reduced MACE by 20% over roughly 3.3 years.[4] The cardiovascular benefit appeared in people who weren't diabetic, which means glycemic control isn't the whole explanation.

“Mediation analyses suggest that weight loss accounts for less than half of the cardiovascular benefit.”

The STEP-HFpEF trial added another piece: in patients with heart failure with preserved ejection fraction and obesity, semaglutide significantly improved symptoms, functional capacity, and a composite endpoint of cardiovascular death and heart failure events.[5] HFpEF is one of the most treatment-resistant conditions in cardiology. That these drugs move meaningful endpoints in that population was not expected.

Renal benefits appeared as secondary outcomes in the cardiovascular trials before anyone ran a dedicated kidney study. Multiple CVOTs showed reduced albuminuria and slowed eGFR decline with GLP-1 agonists.

The FLOW trial (2024) was the first purpose-built kidney outcomes trial in this class. In 3,533 patients with type 2 diabetes and CKD, semaglutide 1 mg reduced the primary kidney composite endpoint — including 50% eGFR decline, kidney failure, and kidney or cardiovascular death — by 24% versus placebo.[6] For a patient population with limited pharmacological options, this is a clinically meaningful result.

Meta-analyses across 13 cardiovascular outcomes trials (83,258 patients) confirm kidney protection specifically in patients with baseline eGFR below 60 mL/min/1.73m², with the effect most pronounced in those with the most impaired baseline function. The mechanisms appear to involve reduced intraglomerular pressure, anti-inflammatory signaling, and direct tubular effects — again, not fully explained by weight loss or glucose control.

The GLP-1 data keeps expanding into unexpected territory:

A drug class that generates this much enthusiasm requires proportionate honesty about its limitations.

FDA approvals cover adults with BMI ≥30, or ≥27 with a weight-related comorbidity. The cardiovascular benefit data from SELECT has prompted many cardiologists to consider GLP-1 agonists specifically for patients with established cardiovascular disease and obesity, regardless of diabetes status.

In precision medicine terms, the patients with the most compelling indication have genuine cardiometabolic disease — elevated cardiovascular risk, insulin resistance, established heart or kidney disease — where the organ-protective effects documented in the large outcomes trials are the primary therapeutic target, with weight loss as part of the mechanism.

A 52-year-old with a BMI of 31, coronary artery disease, and insulin resistance is a different conversation than a 29-year-old with a BMI of 27 and no metabolic comorbidities. The evidence is most robust for the former. The latter deserves a more careful discussion, because the trials that generated the compelling data were built on higher-risk populations, and extrapolating freely to lower-risk patients means working outside the evidence base.

These drugs reduce cardiovascular events, protect kidney function, improve heart failure outcomes, and may have benefits across additional organ systems that are still being characterized. That is a remarkable profile, and the evidence for it is from large, rigorous, well-replicated trials.

They also carry real side effects, require long-term use to maintain benefit, and involve risks that deserve honest discussion — not minimization in the service of enthusiasm.

Managing GLP-1 agonists well means knowing which patients are the right candidates, setting accurate expectations about what treatment requires and what happens when it stops, monitoring for side effects that warrant dose adjustment or discontinuation, and reassessing regularly as both the evidence and the patient's circumstances evolve.

The drugs are genuinely impressive. That doesn't change what good clinical medicine requires.